{"id":"conbercept-prn","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL2108313","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Conbercept functions as a VEGF/PlGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc region of human immunoglobulin G1. This design allows it to sequester circulating VEGF and PlGF, preventing their interaction with endogenous receptors and thereby inhibiting pathological angiogenesis and vascular permeability. It is administered via intravitreal injection for retinal diseases.","oneSentence":"Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:22.823Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular age-related macular degeneration (wet AMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"}]},"trialDetails":[{"nctId":"NCT04782115","phase":"PHASE2","title":"Evaluation of RC28-E Injection in Diabetic Macular Edema","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-17","conditions":"Diabetic Macular Edema","enrollment":156},{"nctId":"NCT03971162","phase":"NA","title":"Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization","status":"COMPLETED","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2019-06-13","conditions":"Myopic Choroidal Neovascularisation","enrollment":50},{"nctId":"NCT03630952","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-12-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT02802657","phase":"PHASE4","title":"Efficacy and Safety of \"Treat-and-Extend\" Regimen Versus \"Pro Re Nata\" of Conbercept in Age-related Macular Degeneration","status":"UNKNOWN","sponsor":"Xiaodong Sun","startDate":"2016-09","conditions":"Age-related Macular Degeneration","enrollment":141},{"nctId":"NCT04380974","phase":"PHASE4","title":"Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy","status":"UNKNOWN","sponsor":"Xiaodong Sun","startDate":"2020-06","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":102},{"nctId":"NCT02821520","phase":"PHASE4","title":"Initial Versus Delayed PDT Combination With Conbercept in PCV","status":"COMPLETED","sponsor":"The Eye Hospital of Wenzhou Medical University","startDate":"2017-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":80},{"nctId":"NCT03973125","phase":"EARLY_PHASE1","title":"Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-08-28","conditions":"Circumscribed Choroidal Haemangioma","enrollment":50},{"nctId":"NCT03571282","phase":"EARLY_PHASE1","title":"Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-06","conditions":"Circumscribed Choroidal Haemangioma","enrollment":50},{"nctId":"NCT02934841","phase":"PHASE2","title":"Conbercept in Choroidal Neovascularization Secondary to Uveitis","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2016-11","conditions":"Choroidal Neovascularization, Uveitis","enrollment":40},{"nctId":"NCT02857517","phase":"PHASE2","title":"Intravitreal Conbercept for Idiopathic Choroidal Neovascularization","status":"UNKNOWN","sponsor":"Jiao Mingfei","startDate":"2016-06","conditions":"Idiopathic Choroidal Neovascularization","enrollment":50},{"nctId":"NCT02194634","phase":"PHASE3","title":"Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2014-07","conditions":"Diabetic Macular Edema","enrollment":248},{"nctId":"NCT01809223","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-08","conditions":"Choroid Neovascularization Secondary to Degenerative Myopia","enrollment":176},{"nctId":"NCT01809236","phase":"PHASE2","title":"Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-05","conditions":"Retinal Vein Occlusion","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"conbercept, PRN","genericName":"conbercept, PRN","companyName":"Chengdu Kanghong Biotech Co., Ltd.","companyId":"chengdu-kanghong-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}